Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism Sodium channels blockers |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationRare Pediatric Disease (US), Orphan Drug (EU) |
Molecular FormulaC15H11F6N5O2 |
InChIKeyBFXBSYMVTNEFRF-UHFFFAOYSA-N |
CAS Registry2392951-29-8 |
Start Date23 Aug 2023 |
Sponsor / Collaborator |
Start Date02 Aug 2023 |
Sponsor / Collaborator |
Start Date19 Jun 2020 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
SCN2A encephalopathy | Phase 2 | US | 02 Aug 2023 | |
SCN2A encephalopathy | Phase 2 | ES | 02 Aug 2023 | |
SCN8A-related epilepsy with encephalopathy | Phase 2 | US | 02 Aug 2023 | |
SCN8A-related epilepsy with encephalopathy | Phase 2 | ES | 02 Aug 2023 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 2 | 16 | (pcvizmwdel) = rofmpbughl kaaylydvwe (kolevjzrex ) View more | Positive | 03 Sep 2024 | |||
Placebo | esgnjktdqk(vguvhcwmqg) = snurxyoipk fznthmbvwu (gmkquqbvky ) | ||||||
Phase 1 | - | 112 | vyakcdhmjx(jbdyqcnbsv) = modest AUC increase (14%) ikjxvqkbuc (nbjhwdtwdb ) View more | Positive | 04 Sep 2023 |